MRSN (Mersana Therapeutics) 3-Year EBITDA Growth Rate : -0.50% (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Mersana Therapeutics 3-Year EBITDA Growth Rate?

Mersana Therapeutics's EBITDA per Share for the three months ended in Sep. 2024 was $-0.08.

During the past 3 years, the average EBITDA Per Share Growth Rate was -0.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -2.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Mersana Therapeutics was 23.40% per year. The lowest was -51.40% per year. And the median was 2.00% per year.

Competitive Comparison of Mersana Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Mersana Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mersana Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mersana Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Mersana Therapeutics's 3-Year EBITDA Growth Rate falls into.

Mersana Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Mersana Therapeutics (NAS:MRSN) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Mersana Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Mersana Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Mersana Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mersana Therapeutics Inc (NAS:MRSN) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

0M4:Germany

Address

840 Memorial Drive, Cambridge, MA, USA, 02139

Website

https://www.mersana.com

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.

Executives

Mohan Bala	officer: SVP, Chief Development Officer	C/O MERSANA THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Brian Deschuytner	officer: Sr. VP, Finance & Product stgy	840 MEMORIAL DRIVE, CAMBRIDGE MA 01776
Ashish Mandelia	officer: VP, Controller	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Timothy B Lowinger	officer: Chief Scientific Officer	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Alejandra Carvajal	officer: Chief Legal Officer	C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139
Huber Martin H. Jr.	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Anna Protopapas	director, officer: President and CEO	MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Tushar Misra	officer: Chief Manufacturing Officer	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Arvin Yang	officer: Chief Medical Officer	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Hack Andrew A. F.	director	300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Michael J. Kaufman	officer: Sr VP Chmistry, Man & Control	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Allene M. Diaz	director	C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Eva M. Jack	officer: CBO, Treasurer & Secretary	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Lawrence M Alleva	director	1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451